For the first time in more than half a century, the United States appears closer than ever to rewriting a major chapter of its federal drug policy. The decades-old system that classifies controlled substances—a framework that has shaped everything from criminal sentencing to medical research—may soon undergo one of its most significant transformations since its creation. At the center of this potential shift is a question that has long hovered at the intersection of science, politics, and culture: Should cannabis continue to be classified as a Schedule I substance?

For generations, the scheduling debate simmered at the margins of political discourse, overshadowed by the broader “War on Drugs” mindset that dominated federal policy from the 1970s onward. But today’s landscape is markedly different. Public attitudes have evolved, scientific evidence has expanded, and state-level legalization has reshaped expectations. The conversation that once elicited political caution is now driven by bipartisan momentum, medical advocacy, and economic reality. What was once dismissed as fringe policy is now considered overdue reform.